Kevin Knobloch will lead Greentown Labs as CEO. Photo via LinkedIn

The largest climatetech incubator in North America has named an Obama Administration appointee as its next CEO.

Kevin Knobloch, who served as chief of staff of the United States Department of Energy in President Barack Obama’s second term, will be CEO of Greentown Labs, effective September 5. In his role, Knobloch will oversee both Greentown locations in Houston and Somerville, Massachusetts, outside of Boston.

“Kevin has a proven and impressive track record of growing, operationalizing, and leading a dynamic mix of organizations at different stages and in various industries, all of which have aligned with his unwavering commitment to addressing the climate crisis,” Greentown Labs Board Chair Dawn James says in a news release. “On behalf of the entire Board of Directors, I am thrilled to welcome Kevin as our next CEO. We are excited for what is to come under Kevin’s leadership and look forward to the positive impact he will undoubtedly have on our team, our startup community, and the ecosystem at large.”

With 30 years of experience across sectors, Knobloch most recently served as president of Knobloch Energy, an independent advisory and consulting firm. He also served as acting executive director of the National Offshore Wind Research & Development Consortium from June through December 2022. From 2018 to 2020, Knobloch was president of New York OceanGrid LLC, where he led Anbaric’s efforts to develop offshore wind transmission in New York.

“I’m honored and thrilled to have the opportunity to once again pass the leadership baton,” Greentown Co-Founder Jason Hanna says, who has been serving as interim CEO. “Especially so given Kevin’s incredible record of climate leadership. I’m excited for the future of this organization and the impact he can make as Greentown enters the second decade of its climate mission.”

The appointment follows an executive search that began after Greentown's previous CEO Emily Reichert announced she was stepping down in December.

“I’m delighted to be asked by Greentown Labs’ Board of Directors to be the next leader of this highly effective organization—and very excited to get to work,” Knobloch says in a statement. “I’ve long admired the critical role Greentown plays in supporting the growth and impact of early-stage climate and energy transition technology companies, as well as the impressive efforts by former longtime CEO Emily Reichert and the talented Board and staff to build Greentown into a national powerhouse and model for other incubators around the world. The climate crisis demands that we accelerate our collective pace of deployment and I look forward to collaborating with our startups, staff, and partners to support that acceleration.”

The announcement comes on the heels of Greentown naming its inaugural Houston general manager. Timmeko Moore Love was named to that new position last week.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”